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Abstract
Background: Ensuring that a trial is designed so that its participants reflect those who might benefit from the
results, or be spared harms, is key to the potential benefits of the trial reaching all they should. This paper describes
the process, facilitated by Trial Forge, that was used between July 2019 and October 2020 to develop the INCLUDE
Ethnicity Framework, part of the wider INCLUDE initiative from the National Institute for Health Research to improve
inclusion of under-served groups in clinical research studies.
Methods: Development of the Framework was done in seven phases: (1) outline, (2) initial draft, (3) stakeholder
meeting, (4) modify draft, (5) Stakeholder feedback, (6) applying the Framework and (7) packaging. Phases 2 and 3
were face-to-face meetings. Consultation with stakeholders was iterative, especially phases 4 to 6. Movement to the
next phase was done once all or most stakeholders were comfortable with the results of the current phase. When
there was a version of the Framework that could be considered final, the Framework was applied to six trials to create
a set of examples (phase 6). Finally, the Framework, guidance and examples were packaged ready for dissemination
(phase 7).
Results: A total of 40 people from stakeholder groups including patient and public partners, clinicians, funders,
academics working with various ethnic groups, trial managers and methodologists contributed to the seven
phases of development. The Framework comprises two parts. The first part is a list of four key questions:
1. Who should my trial apply to?
2. Are the groups identified likely to respond in different ways?
3. Will my study intervention make it harder for some groups to engage?
4. Will the way I have designed the study make it harder for some groups to engage?
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The second part is a set of worksheets to help trial teams address these questions. The Framework can be used
for any stage of trial, for a healthcare intervention in any disease area. The Framework was launched on 1st
October 2020 and is available open access at the Trial Forge website: https://www.trialforge.org/trial-forge-centre/
include/.
Conclusion: Thinking about the number of people in our trials is not enough: we need to start thinking more
carefully about who our participants are.
Keywords: Ethnicity, External validity, Inclusion, Randomised controlled trials, Methodology
The INCLUDE Ethnicity Framework
This paper describes the process used to develop the IN-
CLUDE Ethnicity Framework, which was launched on
1st October 2020 (https://www.trialforge.org/trial-forge-
centre/include/). The Framework was developed to help
trial teams to think about the ethnicity of the people
who should be involved in their trials as participants
(and the trial team, especially patient and public part-
ners), and how to facilitate their involvement. We have
chosen to describe the process of how the Framework
was developed, especially with regard to our external
consultation, and because it might serve as a model that
others could use for similar work.
The Framework consists of four key questions and a
set of worksheets to help trial teams to reflect on how to
foster inclusion for the relevant groups given the context
of the trial. Figure 1 shows the final four questions and
the full INCLUDE Ethnicity Framework is in Supple-
mentary File 1. The Framework is part of the broader
INCLUDE initiative (https://sites.google.com/nihr.ac.uk/
include/) from the National Institute of Health Research
(NIHR), the UK’s biggest public funder of trials, which
aims to improve inclusion of under-served groups in
clinical research studies [1]. While INCLUDE is con-
cerned with all under-served groups, the INCLUDE Eth-
nicity Framework focuses on identifying the ethnic
groups needed for a trial and on identifying challenges
to ensuring their inclusion. The Framework can be used
for any stage of trial, for a healthcare intervention in any
disease area and is aimed primarily at the people who
design and run trials, clinicians and others who plan and
design studies.
Background
Randomised trials are important because done well they
can change the health of, and the care received by, mil-
lions of people worldwide. Ensuring that a trial is de-
signed so that the people in the trial reflect those who
might benefit from the results, or be spared harms, is
key to the potential benefits of the trial reaching all they
should. This means thinking carefully about exactly who
should participate in the trial.
This does not always happen. Narrow eligibility criteria,
reliance on recruitment strategies that work for some but
not all (e.g. postal invitations), assuming everyone has the
same trust in health research, and a perception that some
groups are more difficult or costly to recruit (e.g. due to
language barriers) means trials do not always include
members of the community for whom the trial interven-
tion is a potential treatment. Examples of groups under-
served by trials include pregnant people, older adults,
those with multiple long-term conditions, the socioeco-
nomically disadvantaged, or those with disabilities to
name a few [1]. Ethnic minority groups are often under-
represented in trials despite being 1 in 8 of the UK popu-
lation and frequently having most to gain clinically [2, 3].
In a review of 12 trials for patients with type 2 diabetes,
the mean percentage of South Asian recruits in eight of
them was 5.5% despite South Asians representing 11.2%
of the UK type 2 diabetes population [3]. The other four
studies did not report ethnicity. Despite ethnic minority
involvement being part of the US National Institutes of
Health peer-review process for 20 years, ethnic minority
individuals remain both disproportionately burdened with
cancer and under-represented in cancer trials [4]. The US
Food and Drug Administration issued guidance in
November 2020 recommending that more inclusive trial
enrolment practices should be adopted to ensure that
study populations look like community populations that
might use the drug if approved [5].
Not all trials need to be mirror images of the commu-
nities they serve. There may be no reason to suspect bio-
logical, social or cultural differences between those
inside and outside the trial. The safety and effectiveness
of the treatment might then be anticipated to be similar,
although there is often neither data nor scientific under-
standing to support this assumption. However, there are
at least four reasons why trial teams should always think
carefully about who needs to be in the trial:
1. Sometimes there are treatment differences. In
diabetes, there is evidence that age and genetic
factors all contribute to metformin discontinuation
in the absence of treatment failure, with age
dominating [6]. ACE inhibitors are less effective in
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African Americans for hypertension [7] and some
drug treatments for hepatitis C have markedly
different effects on sustained virologic response
across ethnic groups [8].
2. It is not just about biology. Not all treatments are
based primarily on a biological response—some aim
to achieve behavioural change for example—and
here there will almost always be some variation in
how people from different societal and cultural
backgrounds respond to interventions aiming to
change behaviour. The intervention may not be
appropriate for some members of society to engage
with; culture is known to influence care delivery to
ethnic groups (e.g. how illness and its causes are
perceived, or attitudes towards healthcare
providers) [9]. For example, ethnic minority groups
are at higher risk of mental ill health but are less
likely to access mental health support in primary
care and more likely to end up in crisis care,
strongly suggesting that current service provision is
Fig. 1 The final four key questions of the INCLUDE Ethnicity Framework
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not working for ethnic minority groups [10].
Particular ethnic groups may not be excluded
explicitly but failing to actively promote their
engagement with trials could mean that they are
denied an effective treatment in the future or
continue with a less effective or harmful treatment.
An intervention offered in a place people do not
visit, at a time when they cannot engage, in a
language they do not understand by a person their
community is unable to trust will not benefit these
individuals even if it works well for others in
society.
3. Relevance. If a patient asks the question ‘Do these
results apply to me?’ and the research includes no
one like the patient, it is hard to answer yes with
any confidence. Health professionals may also be
more likely to disregard the results [11].
4. Equity. Everyone should have the same chance to
be included. If under-served groups are margina-
lised in health research, we exacerbate disengage-
ment not only with research, but with healthcare
services in their wider sense.
Developing the INCLUDE Ethnicity Framework
In 2017, the NIHR initiated a project called ‘Innova-
tions in Clinical Trial Design and Delivery for the
under-served (INCLUDE) [1]. INCLUDE aimed to de-
velop a roadmap to identify where research practice
could improve inclusion of under-served groups, as
well as provide a framework for the development of
context-specific guidance to improve inclusion of par-
ticular under-served groups. The Medical Research
Council (MRC) Hubs for Trials Methodology Re-
search Recruitment and Retention Working Group
(now part of the MRC-NIHR Trial Methodology
Research Partnership) was at the same time starting
efforts to improve representation within trials, par-
ticularly of ethnic minority individuals. The two
groups and Trial Forge, an initiative to improve the
efficiency of trials (https://www.trialforge.org), came
together in late 2018 to develop more detailed guid-
ance for one component of the general roadmap:
ethnicity.
Work on the INCLUDE Ethnicity Framework began in
earnest in July 2019. There were seven phases of work
between July 2019 and Sept 2020:
1. Developing an outline of what was needed
2. Developing an initial draft of the Framework
3. Discussing that draft with a wider stakeholder
group
4. Modifying the draft considering feedback from
stakeholders
5. Stakeholder feedback on the modified draft
6. Applying the Framework to 3–5 trials
7. Packaging the Framework, examples and other
materials
A full list of the 40 individuals who participated in
phases 1–7, together with the perspective each consid-
ered they brought to discussions, is available in Supple-
mentary File 2. Most of these were involved because
they were members of INCLUDE, Trial Forge or the
MRC Hubs for Trials Methodology Research Recruit-
ment and Retention Working Group. Phases 3 and 5
were different and involved more external stakeholders
and details of how individuals were selected for these
phases is given below. Figure 2 gives an overview of the
seven phases and the groups contributing to each phase.
Each phase was iterative to some extent but especially
phases 4–6. The shape of iterative development was al-
ways the same: a group of individuals were invited to
comment on an idea or draft, comments collected by the
core project team, the idea or draft was modified and
recirculated for further comment. When there were no
further comments, the core project team accepted that
version as agreed and moved to the next task. We did
not use a formal process for this but our discussion-rich
process produced plenty of comment, changes and even-
tual agreement. Table 1 lists the key points regarding
the development of the INCLUDE Ethnicity Framework.
Phase 1: Developing an outline of what was needed (July
2019–October 2019)
A subgroup of members of INCLUDE, Trial Forge and
the MRC Hubs for Trials Methodology Research Re-
cruitment and Retention Working Group (the core pro-
ject team, a total of ten individuals) discussed, mainly by
email, tasks that needed to be done to support a face-to-
face meeting to be held in Newcastle, UK, in October
2019. The two key conclusions from this phase were:
1. We would need a discussion document for the
meeting that provided an overview of potential
ways of describing ethnic groups. We recognised
that we would need to be clear how we defined
ethnicity for this work and that we would need to
describe this. Although likely to be imperfect, we
also recognised that we would need to categorise
ethnic groups in some way.
2. We needed a list of trial features that potentially
affect the willingness and/or ability of individuals
from different ethnic groups to take part in a trial.
The documents produced in response to #1 and #2 are
Supplementary File 3 and Supplementary File 4,
respectively.
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Phase 2: Developing an initial draft of the Framework
(October 2019–February 2020)
The two documents from phase 1 were discussed on
2nd October 2019 in Newcastle, UK, with the meeting
being attended by all ten individuals who took part in
Phase 1. We also discussed what the future INCLUDE
Ethnicity Framework might look like and who we should
invite to a wider, face-to-face stakeholder meeting. We
agreed that:
1. While we wanted our future Framework to have
global relevance, our choice of ethnic categories
should focus on the UK because INCLUDE is a UK
initiative.
2. Leading from #1, we decided to use the five main
ethnic categories currently used in the UK census
(Table 2). All those present were clear that
categorisation of ethnicity is both challenging and
sensitive and that such social categories are, by
nature, imperfect. We did not feel that developing
an alternative set of ethnic categories to stand in for
those that are in widespread use in the UK was a
helpful option for target end-users of the tool, when
the groups who participate in UK trials tend to be
framed using those categories, sometimes with
greater granularity.
3. We considered the categories to be a minimum—in
other words, trial teams would always have to
consider the UK census categories when designing
their trials with UK participants. However, for a
given trial, this may be insufficient and attention
would need to be given to specific groups within
these categories. We agreed that our guidance
should be clear on this point. Having the ethnic
categories separate to the INCLUDE Ethnicity
Fig. 2 Overview of the seven development phases for the INCLUDE Ethnicity Framework and the groups contributing to each phase
Table 1 The key points regarding the development of the
INCLUDE Ethnicity Framework
Key points
• The INCLUDE Ethnicity Framework is a tool that helps trial teams to
think about how disease prevalence and severity, culture, faith,
language, intervention and trial design features may affect trial
participation of individuals from different ethnic groups.
• A total of 40 people from stakeholder groups including patient and
public partners, clinicians, funders, academics working with ethnic
minority groups, trial managers and methodologists contributed to
seven phases of Framework development.
• The Framework comprises two parts:
Part 1 has four key questions:
1. Who should my trial apply to?
2. Are the groups identified likely to respond in different ways?
3. Will my study intervention make it harder for some groups to
engage?
4. Will the way I have designed the study make it harder for some
groups to engage?
Part 2 is a set of worksheets to help trial teams address these
questions.
• The Framework can be used for any stage of trial, for a healthcare
intervention in any disease area.
• The INCLUDE Ethnicity Framework was launched on October 1st 2020
and is available open access at https://www.trialforge.org/trial-forge-
centre/include/. The site also contains guidance, examples of how the
Framework can be applied to trials and a video giving public
perspectives on why it is important for researchers to think about
ethnicity at the inception of trial planning, throughout the lifespan of
the trial, and/or retrospectively.
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Framework meant that use of the Framework
outside the UK would mainly be about replacing
the ethnic categories with more contextually
appropriate categories rather than having to modify
the Framework itself.
4. We thought all the factors listed as potentially
affecting the willingness and/or ability of different
ethnic groups to participate in a trial
(Supplementary File 3) were relevant. We discussed
others too and agreed that the list should be
extended prior to wider stakeholder discussion.
5. We thought the future INCLUDE Ethnicity
Framework would work best as a tabulated
worksheet comprising a series of questions with
space for trial teams to reflect. The features
discussed in #4 would be the questions in the
tabulated worksheet. We also recognised that
funders are key to the effective implementation of
the future Framework. We thought of this in the
same way as Public and Patient Involvement, which
became widespread in the UK and elsewhere once
major funders required it. The first draft of the
Framework is Supplementary File 5; this version
was used in Phase 3.
6. We agreed an initial list of potential invitees for the
future stakeholder meeting, which we aimed to hold
in early 2020.
Phase 3: Discussing the initial draft with a wider
stakeholder group (February 2020–March 2020)
A face-to-face meeting with stakeholders was held in
London, UK, on 4th February 2020. The meeting had 17
participants of whom six were patient and public
representatives. The latter included the patient and pub-
lic representative from the core project team, two indi-
viduals identified through other ethnicity work being
done in Aberdeen and three individuals identified
through www.peopleinresearch.org, NIHR website to
identify members of the public interested in contributing
to research design. Five of the six patient and public rep-
resentatives brought a perspective that they considered
to Black British, Black African, Black-African-British,
Black British-Ghanaian, or British South Asian. One par-
ticipant did not list ethnicity in his perspective and one
participant preferred not to be named or to state a per-
spective. In addition to representation from patients and
public, the core project team thought the meeting
needed representation from clinicians, academics with
experience of working with ethnic minorities, funders,
trial methodologists, linguists, individuals with experi-
ence in facilitating public involvement in setting research
agendas, research design support services and ethics
committees. We used our personal contacts to identify
potential individuals and were successful in involving
stakeholders from all groups except research design sup-
port services. Our ethics committee representative could
not attend on the day but did contribute afterwards.
After a brief presentation on the INCLUDE initiative,
participants had an open plenary discussion on the draft
Ethnicity Framework (Supplementary File 5), which fo-
cused on first impressions and thoughts. Two small
group discussions later in the day asked more specific
questions:
1. Group work #1 – We came up with three key
design considerations: (1) characteristics of a
particular ethnic group that might influence the
effect of treatment, (2) the intervention and (3) trial
design and delivery. We asked small groups to
consider whether there was something missing in
this list, or whether something needed to be
changed.
2. Group work #2 – Given Group work #1, what can
we give to trialists to help them to achieve more
appropriate ethnic diversity in their trial
populations? We want something that will achieve
change and is practical.
These discussions were wide-ranging and among other
things covered use of the term ‘under-served’ rather than
alternatives. Discussions emphasised the importance of
trial teams asking the question ‘For whom will the trial
results be important?’ and acknowledged the challenges
of categorising ethnicity, including for reasons of indi-
vidual and group identity. We also underscored the im-
portance of trial teams reflecting on the impact culture
and beliefs may have on trial engagement, highlighted
Table 2 The ethnic categories used by the UK census
Broad category Sub-categories
White • English/Welsh/Scottish/Northern Irish/
British
• Irish
• Romani or Irish Traveller
• Any other White background
Mixed/multiple ethnic groups • White and Black Caribbean
• White and Black African
• White and Asian
• Any other mixed/multiple ethnic
background









• Any other Black/African/Caribbean
background
Other ethnic group • Arab
• Any other ethnic group
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other ongoing work and tools broadly focusing on ethni-
city and health and underlined that trial teams need to
build trust and engage more with their communities if
under-served populations are to be better served. The
full summary from the meeting is Supplementary File 6.
A key suggestion was to get trial teams to think more
about the composition of their target and trial popula-
tion at the design stage by asking them four key
questions:
1. Who should my trial apply to?
2. Are the groups identified likely to respond in
different ways?
3. Will my study intervention make it harder for some
groups to engage?
4. Will the way I have designed the study make it
harder for some groups to engage?
Originally, we had anticipated that these questions
would be accompanied by examples, but it was sug-
gested that too much ‘spoon-feeding’ would encourage a
checklist approach rather than encourage teams to re-
flect and think more deeply about the populations they
serve. A key implementation decision was therefore to
create a form with just the main questions followed by
blank spaces for teams to write in to stimulate such
thought, with examples provided elsewhere to help with
understanding of the questions and how ethnicity might
interface with the questions posed.
This suggestion captured much of the discussion in a
concrete and actionable way. We also agreed some prin-
ciples for future work:
 The purpose of this work is to better serve ethnic
minority groups in health research, especially within
the National Health Service (NHS).
 The target audience for our materials is primarily
those who design and deliver trials.
 The target behaviour to support is the routine
consideration of ethnicity.
 We need to consider what success looks like, which
implies that it can be measured.
The main action coming from the meeting was to
embed the four key questions into a new draft of the
Framework, while bearing in mind the principles and
other suggestions noted in the meeting summary. This
included the need for a small example set of trials to
which the Framework had been applied.
Phase 4: Modifying the draft considering feedback from
stakeholders (June 2020–July 2020)
Work on the Framework was delayed by the outbreak of
the COVID-19 pandemic, which took hold in the UK in
early March 2020. Work re-started in June 2020 with
funding received from the UK Research & Innovation
(UKRI)–NIHR COVID-19 Rapid Response call linked to
ethnicity.
The meeting summary from phase 3 was used as the
basis for a new version of the Framework (Supplemen-
tary File 7). All nine of those listed as contributing to
phase 4 in Supplementary File 1 then made iterative
changes to the draft Framework based on email and
video-conference discussions.
We decided to make the four key questions relevant to
all under-served groups but make the tabulated work-
sheets focus specifically on ethnicity. By keeping the four
key questions general, other under-served groups are
not forgotten while at the same time the ethnicity-
focused worksheets could become a model for similar
worksheets in the future for other under-served groups.
The final modified draft from phase 4 that went into the
phase 5 consultation is Supplementary File 8.
Phase 5: Stakeholder feedback on the modified draft (July
2020–August 2020)
Consultation on the draft Framework from phase 4
began as soon as the draft was available and a total of 31
individuals were involved, including all who attended the
February 4th meeting. The core project team also in-
volved an additional academic with experience of work-
ing with ethnic minority groups and the founder of a
patient engagement agency. Comments mainly came by
email, but we also had some videoconferences and an in-
ternal seminar at the Health Services Research Unit,
University of Aberdeen, where the draft Framework was
presented to research staff who had previously had no
involvement with the work.
The response was overwhelmingly positive but there
were many suggestions for improvements, especially to
the worksheets. Changes made in light of feedback
included:
 The addition of more explanatory text to go with
the four key questions and the worksheets. This text
explained the purpose of the questions and
worksheets, that patient and public partners need to
be involved and that there are potential differences
within ethnic groups, i.e. that ethnic groups are not
homogenous.
 Dropping the word ‘biological’ from the worksheets
in favour of ‘disease’. There was inconsistency in our
use of these words and we favoured the use of the
term ‘disease’.
 Adding text to make clear which of the key
questions a particular worksheet helped the trial
team to address.
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 Adding a new question to the worksheets to ask
whether people in each ethnic group might access
healthcare differently.
 Adding a new question to the worksheets to ask
whether the trial outcomes themselves, or other
data being collected, might limit participation.
 Adding a new reference in the worksheets to video
calls as an example mode of delivery for the
intervention or comparator.
 Made substantial presentational changes to the
tables, for example giving each question its own row
in the table and to number the worksheets for ease
of reference.
 Numerous minor text changes and typographical
corrections.
By late July 2020, we had a version of the Framework
that we could begin use in phase 6 while additional feed-
back was still coming in. The late August version of the
Framework used for most of the phase 6 work is Supple-
mentary File 9.
Phase 6: Applying the Framework to 3-5 trials (July 2020 -
Aug 2020)
One of the suggestions coming from the February 2020
meeting was that we should prepare a small set of exam-
ples of real trials to which the Framework had been ap-
plied. The nature of the UKRI-NIHR COVID-19 funding
we received meant that at least some of these had to be
COVID-19 trials. We also wanted to include a type 2
diabetes trial because we already knew prevalence is
higher in some ethnic groups than others, and we
wanted a mix of intervention types and settings. We se-
lected the following six trials:
1. By Band Sleeve – a UK bariatric surgery trial
(http://www.isrctn.com/ISRCTN00786323).
2. COVAC1 – a UK trial evaluating a potential
vaccine for COVID-19 (http://www.isrctn.com/
ISRCTN17072692).
3. iQuaD – a UK community-based periodontal dis-
ease prevention trial (http://www.isrctn.com/
ISRCTN56465715).
4. PRINCIPLE – a UK trial for community-based
treatment of COVID-19 (http://www.isrctn.com/
ISRCTN86534580).
5. RECOVERY – a UK platform trial evaluating
treatments for COVID-19 (http://www.isrctn.com/
ISRCTN50189673).
6. TriMaster – a UK type 2 diabetes treatment trial
(http://www.isrctn.com/ISRCTN12039221).
The Aberdeen-based team divided these trials between
them so that the Framework was applied to each trial
independently by two people. The exception was RE-
COVERY, which was the first trial to which we applied
the Framework and all four of the Aberdeen team inde-
pendently applied the Framework to this trial. Consen-
sus was then reached between the pairs of assessors (or
four for RECOVERY) on the final completed Framework
for each trial.
We had no pre-formulated method for answering the
worksheet questions, but the approach taken by all as-
sessors was the same: web-based searching. This was not
formal, systematic searching (as done for a systematic
review) but more ad hoc, looking for information that
could shed some light on potential challenges and issues.
We recognised that retrospectively applying the Frame-
work to trials with which we had little or no involve-
ment (iQuaD was the only trial where there was
Aberdeen involvement) was not the way in which the
Framework is intended to be used. The information in
our example worksheets may therefore not be a proper
reflection of the trial because we did not have in-depth
knowledge of the field, or access to all the trial materials.
We added a statement making this point to the begin-
ning of each example, together with the names of the as-
sessors and the web-links to the main sources of
information about the trial that we used (namely trial
registration documents, the protocol and study website
if there was one). We discussed the way we answered
the worksheet questions with three of our patient and
public partners and two independent researchers with
experience of working with ethnic minority groups.
Their feedback was overwhelmingly positive. Prior to
completing the examples, all six were checked for
consistency with each other in terms of language and
presentation.
Table 3 gives examples of the sort of challenges to di-
verse ethnic group involvement that using the Frame-
work helps trial teams to identify. These are all taken
from the six trials listed above and the fully completed
Frameworks for these trials are available at https://www.
trialforge.org/trial-forge-centre/include/. We will upload
more examples as they become available.
Phase 7: Packaging the Framework, examples and other
materials (August 2020–September 2020)
The final stage of our work was to package the IN-
CLUDE Ethnicity Framework together with some brief
guidance, the examples and other materials to support
the use of the Framework. This packaging work involved
a design company as well as video staff at the Centre for
Black and Minority Ethnic Health at the University of
Leicester. The resources include a video giving public
perspectives as to why thinking more carefully about
ethnicity when designing trials is important. We also
provide some resources to help trial teams address any
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participation challenges highlighted by using the
Framework.
All of our materials are available at https://www.
trialforge.org/trial-forge-centre/include/.
Discussion
COVID-19 has shone a very bright, and very harsh, light
on researchers’ failure to routinely consider ethnicity
when designing trials [12, 13]. But while the light may
be relatively new, the problem is not. The INCLUDE
Ethnicity Framework aims to help trial teams to system-
atically consider who needs to be involved in their trial
and which elements of the intervention and the trial de-
sign may present challenges for that involvement. With-
out this, the trial results are unlikely to be relevant to
the care of all those who could benefit—inclusion is cer-
tainly an issue of moral and social justice but it is also
an issue of science.
The Framework is new, imperfect, and does not offer
solutions to all of the challenges it may highlight. Using
it does not guarantee that trialists will get the right eth-
nic representation, or that inequalities will be corrected.
But reflecting on the questions the Framework asks will
make trial teams think more about the communities
they serve and move us in the right direction.
Potential downsides to using the INCLUDE Ethnicity
Framework
We believe there are clear potential benefits to using the
Framework, but there are also some potential negatives,
and these are worth mentioning.
Firstly, there is a danger that the Framework could lead to
quotas. This is not our intention. Careful use of the Frame-
work should help trial teams to identify the mix of ethnic
groups needed for their trial, and this will vary from trial to
trial. Secondly, using the Framework will increase the work-
load for trial teams. The process of completing the Frame-
work requires a modest amount of work, but the work of
engaging with potential participants, and implementing
changes to alleviate the barriers that the completed Frame-
work highlights are potentially significant. It is likely that new
or additional trial processes will be needed to engage a wider
range of ethnic groups and there is no shying away from the
fact that this will add both work and expense. However,
using the Framework when developing grants should help to
provide a justification to funders for that work and expense.
Thirdly, it is quite possible that a trial team genuinely aiming
for a diverse population will recruit more slowly than a trial
team that pays less attention to who is in the trial. Changing
this needs a larger set of evidence-informed resources for en-
gaging different ethnic groups than is available at present. It
also needs funders to take a broad view of trial costs. Time
Table 3 Example text taken from the INCLUDE Ethnicity Frameworks for the By-Band-Sleeve, COVAC1, iQuaD, PRINCIPLE, RECOVERY
and TriMaster trials. The fully completed Frameworks for all six trials are available at https://www.trialforge.org/trial-forge-centre/
include/. As we note in the Frameworks themselves, the information may not be a proper reflection of the trial because we did not
have in-depth knowledge of the field or access to all the trial materials
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and money invested in trials recruiting diverse populations
are likely to deliver more relevant research, with a conse-
quent reduction in research waste and misallocated health-
care resources in the longer term. Finally, the Framework is
new and there is no clear ‘best’ way to use it. This will lead
to inconsistency in how it is used; it may also lead to frustra-
tion. We use ethnicity categories but, of course, individuals
within ethnic groups are not homogenous; there is a danger
that some Framework users may rely on stereotyping (e.g.
linked to language skills, or faith-based beliefs) rather that
speaking to people from the ethnic groups concerned.
We do not think that the above are sufficient justifica-
tion for not using the Framework. However, we do think
is worth being aware of these potential negatives, if only
to make sure that counter-arguments are built into trial
design proposals. We welcome suggestions for how the
Framework can be improved, descriptions of how trial
teams used it and how trial design decisions were influ-
enced by its use. Any feedback can be built into future
versions of the Framework and, potentially, influence
similar work for other under-served groups. Please send
comments to info@trialforge.org.
The future
As with Patient and Public Involvement and Engage-
ment in trials, funders have a key role to play in the
adoption of INCLUDE and the INCLUDE Ethnicity
Framework. Funders can help by signposting applicants
towards these materials in their guidance for applicants.
Better still would be to also make it clear to applicants
that consideration of equity, diversity and inclusion will
be part of the review process, as both NIHR and the
Wellcome Trust already do. We consider such moves to
be a sign of success for the mission of INCLUDE and
the Ethnicity Framework to promote inclusion, more
relevant research and a more equitable society.
Although our work has had a UK and Ireland focus, we
think the questions the Framework asks are likely to be rele-
vant elsewhere. Indeed both INCLUDE and the Framework
are already being highlighted outside the UK, Belgium’s KCE
Trials for example includes them in its resources for trialists
(https://kce.fgov.be/en/useful-links-resources-for-
investigators). In our discussions of the Framework with col-
leagues outside the UK and Ireland, the key challenge for
international use is not whether the Framework questions
are relevant but how to tailor the discussion of ethnicity to
the country. Ethnicity is a complex and sensitive topic and
there are sometimes substantial differences in how countries
approach it, as we found in our work (see Supplementary File
3). This is why we refer to ‘ethnic groups’ in the Ethnicity
Framework itself rather than to specific ethnic groups or a
particular system of categorisation.
We think that the main modification for a non-UK or
Ireland version of the Ethnicity Framework is to develop a
country-specific version of our Appendix 1 ‘Ethnic cat-
egories’ document at https://www.trialforge.org/trial-
forge-centre/include/, with more minor changes needed
to the Framework itself depending on the language of eth-
nicity in the country of interest. We have yet to do this,
but we would be very interested in hearing from groups
outside the UK and Ireland who would like to try.
Our Framework focuses on ethnicity but the wider IN-
CLUDE initiative [1, 14] has a much broader remit, ac-
knowledging that there are many groups in society that
have been forgotten, ignored and under-served by health
research. The INCLUDE Ethnicity Framework provides a
model for how trialists might consider some of these other
groups. The MRC-NIHR Trial Methodology Research
Partnership’s Inclusivity Subgroup is beginning to do this
for people who are socio-economically disadvantaged,
have cognitive impairments or identify as LGBTQIA+.
The Framework could likewise be adapted for other
under-served groups or to consider under-served groups
from multiple categories (including those stated above)
more holistically. The NIHR also has a detailed workplan
on improving equality, diversity and inclusivity (https://
www.nihr.ac.uk/about-us/our-contribution-to-research/
equality-diversity-and-inclusion.htm) for participants in
research and its workforce which will hopefully benefit
from the INCLUDE guidance. The Ethnicity Framework’s
four key questions are already general enough to cover all
groups. It is, however, likely that specific differences will
remain and trial designers will need to think carefully
about who in the community their trial is trying to help.
Finally, the impact of the INCLUDE Ethnicity Frame-
work on the inclusion of different ethnic groups in trials
needs to be assessed and this needs funders and research
networks to collect data from trial teams. There is little
point to the Framework if we do not know whether it has
any impact. The UK’s research infrastructure contains
some strengths in this regard [15] but there remain chal-
lenges, not least the need to more routinely record data
on ethnicity. How to go about recording ethnicity is not
trivial. Those asking questions need to know why they are
doing it and those being asked need to know how their
ethnicity information will help to reduce inequalities [16].
The data need to be reported. At present we would en-
courage trial teams to record and report ethnicity infor-
mation for their trials, but we would not mandate it until
it is clearer how to do this well. Some of us are starting
work in this area and we are optimistic that guidance and
tools will be available in the near future.
Conclusion
Thinking about the number of people in our trials is not
enough: we need to start thinking more carefully about
who our participants are.
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